Histiocyte Society blueprint for Langerhans cell histiocytosis research: from cell-of-origin to a more comprehensive cure

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis2024 · 17 citations
2. 2BRAF‐V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first‐line therapy2024 · 8 citations
3. 3Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis2005 · 127 citations
4. 4The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia2016 · 10,405 citations
5. 5High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy2020 · 25 citations